期刊
NEPHROLOGY DIALYSIS TRANSPLANTATION
卷 35, 期 10, 页码 1739-1746出版社
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfz093
关键词
chronic kidney disease; general hypertensive patients; mean blood pressure; visit-to-visit variability in blood pressure
资金
- National Key Research and Development Program [2016YFE0205400, 2016YFC0903103, 2016YFC0904900, 2018ZX09739, 2018ZX09301034003]
- Science and Technology Planning Project of Guangzhou, China [201707020010, 201607020004, 15020010]
- Science, Technology and Innovation Committee of Shenzhen [JSGG20170412155639040, GJHS20170314114526143]
- National Innovation Team Program [81521003]
- Economic, Trade and Information Commission of Shenzhen Municipality [20170505161556110, 20170505160926390]
- National Natural Science Foundation of China [81730019]
- President Foundation of Nanfang Hospital, Southern Medical University [2017C007, 2018Z009]
- Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University [2017J009]
Background. Data on the association between visit-to-visit variability (VVV) in blood pressure (BP) and the risk of chronic kidney disease (CKD) in general treated hypertensive patients were limited. We aimed to evaluate the relation of VVV in BP with the development of CKD, and examine any possible effect modifiers in hypertensive patients without prior cardiovascular diseases (CVDs) or CKD. Methods. This is a post hoc analysis of the Renal Sub-study of the China Stroke Primary Prevention Trial (CSPPT). A total of 10 051 hypertensives without CVD and CKD and with at least six visits of BP measurements from randomization to the 24month visit were included. The main VVV in BP was expressed as standard deviation (SD). The primary outcome was the development of CKD, defined as a decrease in estimated glomerular filtration rate >= 30% and to a level of <60mL/min/1.73 m(2), or end-stage renal disease. Results. The median treatment duration was 4.4 years. After multivariable adjustment, including baseline systolic blood pressure (SBP) and mean SBP during the first 2-year treatment period, there was a significantly positive relationship of SD of SBP with the risk of CKD development (per SD increment; odds ratio, 1.27; 95% confidence interval: 1.10-1.46). The results were similar for coefficient of variation (CV) of SBP. Results across various subgroups, including age, sex, SBP at baseline, treatment compliance, concomitant antihypertensive medications and mean SBP during the first 24-month treatment period, were consistent. Conclusions. SBP variability, irrespective of mean BP level, was significantly associated with the development of CKD in general treated hypertensive patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据